Enavogliflozin,
does it really help with Improved HbA1c and glycemic control in patients with type 2 diabetes?
research showsC. Enavogliflozin improves HbA1c and glycemic control in type 2 diabetes, but product-specific evidence is concentrated in the 167-participant, 24-week Korean ENHANCE-A trial and a small noninferiority trial against dapagliflozin. ENHANCE-A lowered HbA1c by 0.99 percentage points and fasting glucose by 40.1 mg/dL more than placebo, but these are surrogate outcomes. Daewoong Pharmaceutical funded the program and participated in design, data management, analysis, and writing, while independent replication and molecule-specific cardiovascular or kidney hard outcomes are absent. The surrogate and single-product sponsor ceilings under rules 1 and 2-b therefore yield C with 58 points; hard outcomes from dapagliflozin or the wider class cannot be assigned to enavogliflozin.
ads claimA Korean-developed SGLT2 drug and strong glucosuria or HbA1c lowering can be expanded into automatic prevention of myocardial infarction, heart failure, and kidney failure. Glycemic surrogate improvement and molecule-specific long-term cardiovascular or kidney outcomes are separate questions.
Useful facts when choosing a product
- Pivotal trials used enavogliflozin 0.3 mg once daily; exact indications, combinations, and renal-function criteria should follow the approved label.
- SGLT2 inhibition increases urinary glucose excretion and may also reduce weight and blood pressure, but these changes are not themselves hard-outcome evidence.
- Genital fungal infection, urinary infection, polyuria, dehydration, and hypotension can occur, so infection symptoms and volume status require attention.
- Reduced intake, acute illness, surgery, heavy alcohol use, or insufficient insulin can precipitate ketoacidosis even without marked hyperglycemia, requiring drug interruption and urgent assessment when suspected.
What the research actually shows
Kwak and colleagues randomized 167 Korean adults with type 2 diabetes inadequately controlled by diet and exercise to enavogliflozin 0.3 mg or placebo for 24 weeks. The placebo-adjusted HbA1c difference was minus 0.99 percentage points, and 71% versus 24% reached HbA1c below 7%. Han and colleagues compared enavogliflozin with dapagliflozin in 200 metformin-treated participants; HbA1c changed by minus 0.80% versus minus 0.75%, a between-group difference of minus 0.04 percentage points, 95% CI minus 0.21 to 0.12, meeting noninferiority. A meta-analysis of four trials and 684 participants confirmed 12-to-24-week reductions in HbA1c, fasting glucose, and weight but had substantial heterogeneity and no long-term hard outcomes.
Why this is classified as C (58)
C. ENHANCE-A's HbA1c difference of minus 0.99 percentage points and noninferiority to dapagliflozin support short-term glucose lowering. Twelve-to-24-week surrogates, modest Korean samples, Daewoong funding and analytic involvement, no independent replication, and no molecule-specific cardiovascular or kidney hard-outcome trial trigger the rules 1 and 2-b ceiling of C with 58 points. Genital infection, dehydration, and euglycemic ketoacidosis remain separate safety concerns.
Counterpoint. HbA1c and fasting glucose improve, but patients needing cardiovascular or kidney protection should separately confirm whether the chosen molecule has direct hard-outcome evidence.
Rejudgment record. Reassessment (cross-check reflected) — Accepted the 24-week ENHANCE-A HbA1c effect in 167 Korean participants and small noninferiority evidence against dapagliflozin, but applied the rules 1 and 2-b ceiling of C for surrogate outcomes, Daewoong funding and analytic involvement, no independent replication, and no molecule-specific cardiovascular or kidney hard outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in HbA1c and glycemic control | C | The 167-participant, 24-week Korean ENHANCE-A trial and a small active-control trial improved surrogate outcomes, but independent replication is absent. |
| Extension of class effects to cardiovascular and kidney event prevention | ? | No hard-outcome trial specific to enavogliflozin was identified. |
| Ancillary effects on weight and blood pressure | C | Short trials showed improvement, but these are secondary surrogates with uncertain long-term clinical value. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Kwak SH et al. ENHANCE-A 2023 | Multicenter randomized double-blind placebo-controlled phase 3 trial | 167 | Supported by Daewoong Pharmaceutical with employee coauthors | Change in HbA1c at 24 weeks; fasting glucose and weight | Placebo-adjusted HbA1c was minus 0.99 percentage points, fasting glucose minus 40.1 mg/dL, and weight minus 2.5 kg. | Pivotal placebo-controlled glycemic-efficacy evidence |
| Han KA et al. ENHANCE-M 2023 | Multicenter randomized double-blind active-controlled phase 3 noninferiority trial | 200 | Sponsored by Daewoong, which participated in design, data management, analysis, and manuscript preparation | Noninferiority to dapagliflozin for 24-week HbA1c change | HbA1c changed by minus 0.80% versus minus 0.75%; difference minus 0.04 percentage points (95% CI minus 0.21 to 0.12), meeting noninferiority. | Active-control replication evidence |
| Dutta D et al. 2023 meta-analysis | Systematic review and meta-analysis of randomized trials | 24 | Academic meta-analysis; included trials were largely sponsor-supported | HbA1c, fasting glucose, weight, blood pressure, and adverse events | The mean HbA1c difference versus placebo was minus 0.76 percentage points, with heterogeneity of I-squared 97%. | Synthesis of short-term surrogate evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Enavogliflozin x improved HbA1c and glycemic control in type 2 diabetes — Evidence Grade C·58. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/enavogliflozin-type2-diabetes-hba1c-glycemic-control/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.